Tellurian Inc (TELL) Advances Driftwood LNG Project Amid Financial Flexibility Moves,...
Tellurian Inc. (TELL), closed its last session at $0.8650, matching its opening price for the day. Amidst active trading, today, bids soared...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
HEALIOS K.K., A Partner Of Athersys Inc (NASDAQ:ATHX), Enrolls Patients In...
HEALIOS K.K., an associate of Athersys Inc (NASDAQ:ATHX), completed the enrollment patients in the ONE-BRIDGE trial.
In this clinical trial, the company will evaluate the...
MAKE IT MODERN
LATEST REVIEWS
Autonomix Medical Inc (AMIX) Soars Over 100% Following Strategic Licensing Agreement
Autonomix Medical, Inc. (NASDAQ: AMIX), a trailblazer in medical device technology focused on neurological conditions, has seen its stock soar over 100%...
MAKE IT MODERN
PERFORMANCE TRAINING
Zeeland Pharma A/S (NASDAQ: ZEAL) Doses First Subject in Phase 3b Study Evaluating Glepaglutide...
Zeeland Pharma A/S (NASDAQ: ZEAL) has announced the dosing of the first participants in the Phase 3b study, EASE-SBS 4, assessing glepaglutide, a long-acting...
Agenus Inc (NASDAQ: AGEN) Inks Licensing Deal With Bristol-Myers Squibb Co (NYSE: BMY) To...
Agenus Inc (NASDAQ: AGEN) has partnered with Bristol-Myers Squibb Co (NYSE: BMY). As part of the agreement, Bristol Myers Squibb Co will study an...
Bluebird Bio Inc. (NASDAQ:BLUE) Receives PRIME Designation From EMA For Advancement Od LentiGlobin™ For...
Bluebird Bio Inc. (NASDAQ:BLUE) has announced that it has received eligibility from the European Medicines Agency to the Priority Medicines program (PRIME) for its...
US FDA Gives Nod For Kitov Pharma Lt (NASDAQ:KTOV) To Conduct Phase 1/2 Clinical...
US FDA has accepted the IND Investigational New Drug application and permitted Kitov Pharma Lt (NASDAQ:KTOV) to launch phase 1/2 clinical study of NT219...
The Clinical Study of AT-301 Nasal Spray in the First Group of Participants Had...
When the COVID-19 pandemic first emerged, no one, not even the pharmaceutical industry, was prepared. The world got into a panic mode due to...
MAKE IT MODERN
